Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEO-CM04S1 Vaccine for COVID-19 Prevention
NCT04639466Phase 2Completed
- Sponsor
- GeoVax Labs, Inc.
- Start
- Nov 2020
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GEO-CM04S1 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by GeoVax Labs, Inc. Primary endpoints: Incidence of adverse events at 365 days, Antibody levels to SARS CoV-2 Spike protein at 365 days and 1 more. Started Nov 2020; status: completed.
02
Drugs
GEO-CM04S1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04639466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639466.